64 results
8-K
EX-10.1
ICU
SeaStar Medical Holding Corporation
20 Aug 24
Entry into a Material Definitive Agreement
6:41pm
present such counsel with a conflict of interest, (ii) the actual or potential defendants in, or targets of, any such action include both
8-K
EX-99.1
ICU
SeaStar Medical Holding Corporation
13 Aug 24
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update
4:42pm
proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. The SCD selectively targets the most highly
8-K
EX-99.1
ICU
SeaStar Medical Holding Corporation
14 May 24
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
4:05pm
inflammatory. The SCD selectively targets the most highly activated proinflammatory neutrophils and monocytes. These cells are then returned back
8-K
EX-99.1
ICU
SeaStar Medical Holding Corporation
17 Apr 24
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
4:01pm
monocytes to a reparative state and
promote activated neutrophils to be less inflammatory. The SCD selectively targets the most highly activated
8-K/A
EX-99.1
x0but
27 Mar 24
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
5:23pm
8-K
EX-99.1
kpgtml bxbf6r
27 Mar 24
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
8:32am
424B3
9l1vg8kolav0vzz mb
5 Mar 24
Prospectus supplement
5:08pm
424B3
v9h7j a4fkk0
5 Mar 24
Prospectus supplement
4:59pm
424B3
gea9xqazgp0ykvmh
5 Mar 24
Prospectus supplement
4:56pm
8-K
EX-99.1
oifqmgxcd0spdmxen
22 Feb 24
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
8:00am
8-K
EX-99.1
733e8msi29v zw
21 Nov 23
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
6:04pm
8-K
EX-99.1
mp32o1cfnz2ev uke
30 Oct 23
FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients
8:15am
424B3
ynafsk7uwkolyof7qj
6 Oct 23
Prospectus supplement
1:08pm
424B3
8d961
6 Oct 23
Prospectus supplement
1:06pm
424B3
o7zpegrl l92f4j8
6 Oct 23
Prospectus supplement
1:04pm
424B3
jlwe0ktapzyyp7u
6 Oct 23
Prospectus supplement
12:59pm
8-K
EX-99.1
zctjl6 60
3 Oct 23
Company to finalize labeling with FDA Approvable Letter expected within a month
4:07pm
8-K
EX-99.1
9pchmifc6
14 Aug 23
SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update
6:46pm